AI-generated summary
The authors studied mice with cerulein-induced acute pancreatitis and cultured pancreatic cells treated with cerulein. Mice and cells receiving photobiomodulation showed reduced inflammatory markers and pancreatic edema, and the authors link these changes to ROS-mediated NF-κB signaling. The authors note that clinical studies are needed to confirm efficacy.
- Who or what was studied
- Mice with experimentally induced acute pancreatitis and AR42J pancreatic cells
- Limits stated in the abstract
- Findings come from animal and cell experiments, and the abstract states that clinical studies are needed to confirm efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The prevalence of acute pancreatitis (AP) is increasing, but current treatments remain inadequate. Photobiomodulation (PBM) therapy has demonstrated anti-inflammatory effects under various conditions; however, its role in AP has not been explored. Evaluating this could introduce a noninvasive treatment option for AP. This study aimed to assess PBM’s potential of PBM in reducing cerulein-induced AP inflammation and elucidate the underlying mechanisms. Animal Experiment: Mice were categorized into control, model, and experimental groups. AP was induced with cerulein injections in depilated mice, followed by seven PBM irradiation sessions in the experimental group. Blood samples collected 24 h post-injection were analyzed for TNF-α, IL-6, amylase, and lipase levels. The pancreatic tissue was histologically examined and scored. Cell Experiment: AR42J cells, grouped similarly, were subjected to cerulein exposure and PBM irradiation. An NF-κB inhibitor has been introduced into some groups. Measurements included amylase, NF-κB p65, phosphorylated NF-κB p65, and (Robot Operating System) ROS levels in the supernatant. Animal Experiment: PBM treatment reduced pancreatic tissue edema and serum amylase, lipase, TNF-α, and IL-6 levels. Cell Experiment: ROS levels increased, NF-κB p65 expression decreased, and TNF-α, IL-6, amylase, and lipase in the cell supernatant decreased post-PBM treatment. The addition of the NF-κB inhibitor BAY 11-7082 to the PBM-treated group did not increase ROS levels. PBM therapy shows potential as a noninvasive AP treatment by modulating ROS-mediated NF-κB signaling. Clinical studies are needed to confirm the efficacy and explore the applications of AP treatment.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Reactive oxygen species, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.